Ketoconazole vs Minoxidil
FDA Approved vs FDA Approved
synergistic Researched · 95% The other pillar of the "big 3" stack. Minoxidil stimulates hair growth through vasodilation and prolongation of the anagen phase, while ketoconazole addresses the inflammatory and androgenic components of hair loss. Using both provides multi-pathway coverage.
Molecular Data
Ketoconazole Minoxidil
Weight 531.43 Da 209.25 Da
Half-life Topical application stays local with minimal systemic absorption ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Type Synthetic imidazole antifungal Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
Key Benefits
Ketoconazole
01 Disrupts DHT binding at the follicle level with topical application
02 Reduces Malassezia colonization and scalp inflammation associated with hair loss
03 Negligible systemic absorption when used as a shampoo
04 FDA-approved and widely available over the counter (1%) or by prescription (2%)
05 Part of the established "big 3" hair loss protocol with finasteride and minoxidil
06 Treats concurrent seborrheic dermatitis and dandruff while addressing hair loss
07 Simple to incorporate into existing shower routines
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Side Effects
Ketoconazole
Scalp dryness with regular use
Mild scalp irritation or itching at application site
Changes in hair texture (temporary dryness or coarseness)
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Contraindications
Known hypersensitivity to ketoconazole or any imidazole antifungal
Open wounds or severely broken skin on the scalp
Oral ketoconazole is contraindicated in liver disease (not applicable to shampoo use)
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Research Evidence
Ketoconazole Minoxidil
Status FDA Approved FDA Approved
References 4 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.